购物车
全部删除
您的购物车当前为空
别名 瑞加德松, Lexiscan, CVT-3146
Regadenoson (CVT-3146) 是一种腺苷衍生物和选择性 A2A 腺苷受体激动剂,具有冠状动脉舒张活性,对大鼠和猪腺苷 A2A 受体的Ki 分别为 290 和 1120 nM。它是血管扩张剂,可增加啮齿动物血脑屏障的通透性。

Regadenoson (CVT-3146) 是一种腺苷衍生物和选择性 A2A 腺苷受体激动剂,具有冠状动脉舒张活性,对大鼠和猪腺苷 A2A 受体的Ki 分别为 290 和 1120 nM。它是血管扩张剂,可增加啮齿动物血脑屏障的通透性。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 298 | 现货 | |
| 2 mg | ¥ 423 | 现货 | |
| 5 mg | ¥ 683 | 现货 | |
| 10 mg | ¥ 1,050 | 现货 | |
| 25 mg | ¥ 1,980 | 现货 | |
| 50 mg | ¥ 2,990 | 现货 | |
| 100 mg | ¥ 4,390 | 现货 | |
| 500 mg | ¥ 9,480 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 586 | 现货 |
Regadenoson 相关产品
| 产品描述 | Regadenoson (CVT-3146) is an adenosine derivative and selective A2A adenosine receptor agonist with coronary vasodilating activity. Upon administration, regadenoson selectively binds to and activates the A2A adenosine receptor, which induces coronary vasodilation. This leads to an increase in coronary blood flow and enhances myocardial perfusion. Compared to adenosine, regadenoson has a longer half-life and shows higher selectivity towards the A2A adenosine receptor. This agent is a very weak agonist for the A1 adenosine receptor and has negligible affinity for the A2B and A3 adenosine receptors. |
| 靶点活性 | A2A receptor:290 nM(Ki) |
| 别名 | 瑞加德松, Lexiscan, CVT-3146 |
| 分子量 | 390.35 |
| 分子式 | C15H18N8O5 |
| CAS No. | 313348-27-5 |
| Smiles | CNC(=O)c1cnn(c1)-c1nc(N)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1 |
| 密度 | 1.98g/cm3 |
| 颜色 | White |
| 物理性状 | Solid |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 255 mg/mL (653.26 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.56 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容